Anti-fibrotic potential of erythropoietin signaling on bone marrow derived fibrotic cell.

ABSTRACT:

Introduction

The number of patients with end stage kidney disease (ESKD) are increasing world-side. While interstitial fibrosis (IF) is a common step for the progression to ESKD, therapeutic options for IF is still limited in clinical settings. We have reported that bone marrow-derived fibrotic cell, fibrocyte, is involved in the pathogenesis of kidney fibrosis. Also recent studies revealed that erythropoietin has protective effect on kidney diseases. However, it is unknown whether erythropoietin (EPO) inhibits fibrosis in progressive kidney injury. Therefore, we explored the impacts of EPO on kidney fibrosis with focusing on fibrocyte.

Method

Fibrocyte was differentiated from peripheral mononuclear cells of healthy donor. Fibrocyte was stimulated with transforming growth fa

SUBMITTER: Iwata Y 

PROVIDER: S-EPMC8167964 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature